Hepatitis B vaccination in acute lymphoblastic leukemia
In Leukemia Research
By: Goyal S.
Contributor(s): Advani SH | Kelkar R | Pai SK | .
Material type:
ArticleSeries: Vol 22 Issues 2.Publisher: 1998Description: 193-195.Subject(s): poor seroconversion | immunosuppression | hepatitis B vaccination | ALL | LeukemiaDDC classification: 616.155
In:
Leukemia ResearchSummary: Active immunization against hepatitis B virus infection was carried out in 162 patients with acute lymphoblastic leukemia attending the Outpatient Department at Tata Memorial Hospital. Recombinant DNA vaccine was given in three doses at 0, 1 and 2 months followed by a booster 1 year after the first dose. Antibodies to hepatitis B surface antigen could be detected in 19.7% of patients following vaccination. Of these only 10.5% had titers in the protective range. Immunosuppression induced by both disease and treatment appears to diminish responsiveness to vaccination. Passive active prophylaxis with both vaccine and immunoglobulin may be a more effective alternative in these patients
| Item type | Current location | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|
Articles
|
Tata Memorial Hospital | 616.155 | Available | AR1188 |
Active immunization against hepatitis B virus infection was carried out in 162 patients with acute lymphoblastic leukemia attending the Outpatient Department at Tata Memorial Hospital. Recombinant DNA vaccine was given in three doses at 0, 1 and 2 months followed by a booster 1 year after the first dose. Antibodies to hepatitis B surface antigen could be detected in 19.7% of patients following vaccination. Of these only 10.5% had titers in the protective range. Immunosuppression induced by both disease and treatment appears to diminish responsiveness to vaccination. Passive active prophylaxis with both vaccine and immunoglobulin may be a more effective alternative in these patients
There are no comments for this item.